Although our human being now obtained whole DNA information of mankind, the most of the complex network between proteins has not been unveiled.  It must be meaningless characters without knowing rules and orders, which can translate those characters into real events.  In turn, the real events in the cells are expressed in a form of proteins.

Therefore, we have to be equipped with precise and efficient tools for detecting subtle changes in protein folding, protein modification, and protein interactions in order to investigating and elucidating the cross-talking between large number of proteins.  Most researchers would agree that the best tool for this purpose is an antibody. 

Myxengo is a biotech company founded to provide these valuable tools for post-genome era.  Because Myxengo is managed by a group of highly experienced scientists from both academic and industry, Myxengo have successfully provided highly qualified recombinant antibodies and proteins using our proprietary technologies. Myxengo dreams about a leading antibody company in the world and tries our best effort to satisfy our customer with quality, reliability, promptness, and cost-effectiveness.

Ultimately, Myxengo envisions groundbreaking innovations in the field of bioassays, diagnostics and bio-therapeutics through our technologies. For the achievement of this goal we are diligently looking for synergistic collaborations with bio-reagent or pharmaceutical companies.